Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus
Running, not enrolling · Phase 2 · Has a placebo group
Conditions studied: Obese, Obesity
In brief
This Study is a Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus.
Key facts
- Study ID
- NCT07205900
- Run by
- Hanmi Pharmaceutical Company Limited
- People needed
- 267
- Starts
- 2025-12-02
- Expected to finish
- 2027-01-01
- Last updated by the study team
- 2026-04-08
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- ProSciento Inc — Chula Vista, California, United States
- Accellacare of Duly - Duly Oak Lawn — Oak Lawn, Illinois, United States
- Accellacare of McFarland — Ames, Iowa, United States
- Accellacare of Cary - Cary Medical Group — Cary, North Carolina, United States
- Accellacare of Hickory — Hickory, North Carolina, United States
- Raleigh Medical Group, P.A. — Raleigh, North Carolina, United States
- Accellacare of Piedmont - Piedmont HealthCare — Statesville, North Carolina, United States
- Accellacare of Wilmington, LLC — Wilmington, North Carolina, United States
- Accellacare of Winston Salem — Winston-Salem, North Carolina, United States
- Accellacare of Charleston — Mt. Pleasant, South Carolina, United States
- Accellacare of Bristol-PAC of Tennessee — Bristol, Tennessee, United States
- Bristol-Internal Medicine and Pediatric Associates of Bristol, P.C. — Bristol, Tennessee, United States
- Texas Clinical Research Institute — Arlington, Texas, United States
- Velocity Clinical Research, Dallas — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.